Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 12 04:00PM ET
55.98
Dollar change
-0.32
Percentage change
-0.57
%
IndexRUT P/E- EPS (ttm)-5.40 Insider Own3.29% Shs Outstand114.66M Perf Week0.85%
Market Cap6.42B Forward P/E- EPS next Y-4.37 Insider Trans-7.11% Shs Float110.89M Perf Month5.05%
Income-530.60M PEG- EPS next Q-1.05 Inst Own101.11% Short Float15.67% Perf Quarter-23.51%
Sales3.75M P/S1711.64 EPS this Y17.26% Inst Trans-1.37% Short Ratio8.58 Perf Half Y-44.92%
Book/sh-3.78 P/B- EPS next Y3.09% ROA-62.50% Short Interest17.38M Perf Year58.63%
Cash/sh5.40 P/C10.36 EPS next 5Y15.00% ROE- 52W Range25.98 - 110.25 Perf YTD-32.95%
Dividend Est.- P/FCF- EPS past 5Y-22.79% ROI-161.27% 52W High-49.22% Beta0.75
Dividend TTM- Quick Ratio7.19 Sales past 5Y12.30% Gross Margin-254.77% 52W Low115.47% ATR (14)2.15
Dividend Ex-Date- Current Ratio7.19 EPS Y/Y TTM-17.98% Oper. Margin-13272.04% RSI (14)54.38 Volatility3.25% 3.48%
Employees423 Debt/Eq- Sales Y/Y TTM-96.17% Profit Margin-14141.74% Recom1.44 Target Price82.65
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q3.54% Payout- Rel Volume0.58 Prev Close56.30
Sales Surprise-8.52% EPS Surprise-16.29% Sales Q/Q-81.90% EarningsMay 08 AMC Avg Volume2.03M Price55.98
SMA203.72% SMA500.36% SMA200-1.74% Trades Volume1,169,942 Change-0.57%
Date Action Analyst Rating Change Price Target Change
Jan-24-24Downgrade UBS Buy → Neutral $61 → $92
Jan-05-24Downgrade Morgan Stanley Overweight → Equal-Weight $60 → $90
Nov-09-23Initiated Goldman Buy $50
Nov-07-23Initiated B. Riley Securities Buy $66
Aug-15-23Initiated SVB Securities Outperform $58
Feb-17-23Initiated BofA Securities Neutral $49
Dec-23-22Reiterated Needham Buy $60 → $58
Dec-20-22Initiated Truist Buy $60
Oct-11-22Initiated UBS Buy $80
Jan-28-22Initiated Goldman Buy $74
Jul-11-24 08:00AM
08:00AM
Jul-10-24 01:42AM
Jul-03-24 04:00PM
Jul-02-24 02:46AM
02:11PM Loading…
Jun-26-24 02:11PM
Jun-18-24 01:49AM
Jun-17-24 07:30AM
Jun-12-24 02:37AM
Jun-10-24 07:00PM
Jun-05-24 07:55AM
06:14AM
03:00AM
Jun-04-24 04:00PM
02:38AM
04:00PM Loading…
May-29-24 04:00PM
May-28-24 04:00PM
May-27-24 06:28PM
06:13PM
May-24-24 11:12AM
May-23-24 09:40AM
07:50AM
May-22-24 11:30PM
04:10PM
04:02PM
04:00PM
May-17-24 07:30AM
May-15-24 07:30AM
May-14-24 04:01PM
May-13-24 05:24PM
04:08PM Loading…
04:08PM
09:43AM
09:33AM
09:33AM
09:11AM
May-10-24 12:37PM
May-09-24 10:48AM
10:46AM
07:01AM
May-08-24 09:00PM
05:18PM
05:10PM
04:06PM
04:00PM
07:30AM
07:30AM
02:23AM
May-07-24 05:02PM
04:00PM
02:04PM
May-02-24 04:00PM
May-01-24 10:01AM
Apr-29-24 04:00PM
Apr-26-24 04:44PM
06:00AM
Apr-24-24 04:00PM
Apr-10-24 09:27AM
07:30AM
Apr-09-24 07:00PM
Apr-05-24 07:30AM
Apr-02-24 04:00PM
Apr-01-24 04:00PM
Mar-25-24 08:15AM
Mar-20-24 08:30AM
Mar-18-24 08:01PM
Mar-17-24 08:50AM
Mar-13-24 02:25PM
Mar-12-24 06:46AM
Mar-04-24 04:00PM
Mar-01-24 06:47PM
04:00PM
Feb-29-24 07:30AM
Feb-28-24 10:27AM
10:22AM
07:30AM
Feb-27-24 05:10PM
04:42PM
04:17PM
04:00PM
Feb-13-24 04:00PM
Feb-12-24 12:38AM
Feb-09-24 10:01AM
Feb-08-24 09:10AM
Feb-06-24 04:00PM
Feb-05-24 05:30PM
Jan-29-24 07:30AM
Jan-25-24 07:30AM
Jan-18-24 01:00PM
Jan-12-24 04:40PM
02:47PM
01:07PM
05:27AM
Jan-11-24 04:22PM
04:05PM
12:58PM
12:54PM
12:47PM
12:30PM
Jan-10-24 01:04PM
Jan-09-24 01:17PM
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Blum Robert IPresident & CEOJul 10 '24Option Exercise6.675,76738,466410,912Jul 10 05:24 PM
Blum Robert IPresident & CEOJul 10 '24Sale54.2911,500624,335399,412Jul 10 05:24 PM
Malik Fady IbrahamEVP Research & DevelopmentJul 09 '24Option Exercise7.965,30042,188138,304Jul 09 06:15 PM
Malik Fady IbrahamEVP Research & DevelopmentJul 09 '24Sale55.907,300408,103131,004Jul 09 06:15 PM
Harrington Robert ArthurDirectorJul 05 '24Sale54.6125313,81615,516Jul 08 05:06 PM
PARSHALL B LYNNEDirectorJul 01 '24Option Exercise10.685,00053,40025,600Jul 01 05:12 PM
Blum Robert IPresident & CEOJul 01 '24Sale54.0511,500621,575405,145Jul 01 05:04 PM
PARSHALL B LYNNEDirectorJul 01 '24Sale54.225,000271,10020,600Jul 01 05:12 PM
Malik Fady IbrahamEVP Research & DevelopmentJun 25 '24Option Exercise7.965,30042,188138,304Jun 25 08:04 PM
Malik Fady IbrahamEVP Research & DevelopmentJun 25 '24Sale53.727,300392,143133,004Jun 25 08:04 PM
PARSHALL B LYNNEDirectorJun 17 '24Option Exercise10.685,00053,40025,600Jun 17 05:17 PM
Blum Robert IPresident & CEOJun 17 '24Sale52.6022,5001,183,391416,645Jun 17 05:13 PM
PARSHALL B LYNNEDirectorJun 17 '24Sale52.555,000262,75020,600Jun 17 05:17 PM
Malik Fady IbrahamEVP Research & DevelopmentJun 11 '24Option Exercise7.965,42243,159142,792Jun 11 04:22 PM
Malik Fady IbrahamEVP Research & DevelopmentJun 11 '24Sale53.047,788413,106135,004Jun 11 04:22 PM
Bhanji MunaDirectorJun 10 '24Sale52.072,000104,14017,631Jun 10 04:15 PM
Blum Robert IPresident & CEOJun 04 '24Sale48.8522,5001,099,125439,145Jun 07 04:03 PM
PARSHALL B LYNNEDirectorJun 03 '24Option Exercise10.685,00053,40020,600Jun 04 04:30 PM
Wong RobertVP, Chief Accounting OfficerJun 03 '24Sale48.8813,011635,97816,653Jun 03 04:33 PM
PARSHALL B LYNNEDirectorJun 03 '24Sale48.645,000243,20015,600Jun 04 04:30 PM
Harrington Robert ArthurDirectorJun 03 '24Sale48.641,58076,85115,541Jun 05 05:23 PM
Malik Fady IbrahamEVP Research & DevelopmentMay 07 '24Option Exercise6.6714,18694,621152,603May 07 04:37 PM
Malik Fady IbrahamEVP Research & DevelopmentMay 07 '24Sale65.1115,5471,012,265137,056May 07 04:37 PM
HENDERSON JOHN TDirectorApr 25 '24Sale64.5410,562681,67132,070Apr 25 06:54 PM
Malik Fady IbrahamEVP Research & DevelopmentApr 09 '24Option Exercise6.6728,605190,795171,172Apr 09 04:38 PM
Malik Fady IbrahamEVP Research & DevelopmentApr 09 '24Sale74.3132,6052,422,918138,567Apr 09 04:38 PM
Malik Fady IbrahamEVP Research & DevelopmentMar 05 '24Option Exercise6.6728,604190,789167,577Mar 05 04:05 PM
Malik Fady IbrahamEVP Research & DevelopmentMar 05 '24Sale67.5632,6042,202,606138,973Mar 05 04:05 PM
HENDERSON JOHN TDirectorFeb 14 '24Option Exercise4.445,00022,20047,632Feb 14 04:04 PM
HENDERSON JOHN TDirectorFeb 14 '24Sale76.485,000382,40042,632Feb 14 04:04 PM
Blum Robert IPresident & CEOFeb 13 '24Option Exercise6.6712,50083,375454,297Feb 13 04:01 PM
Blum Robert IPresident & CEOFeb 13 '24Sale76.8512,500960,625441,797Feb 13 04:01 PM
Malik Fady IbrahamEVP Research & DevelopmentFeb 06 '24Option Exercise6.6728,605190,795175,578Feb 06 04:43 PM
Malik Fady IbrahamEVP Research & DevelopmentFeb 06 '24Sale79.3032,6052,585,496142,973Feb 06 04:43 PM
Blum Robert IPresident & CEOJan 31 '24Option Exercise6.6712,50083,375454,297Feb 02 04:41 PM
Blum Robert IPresident & CEOJan 31 '24Sale79.5712,500994,625441,797Feb 02 04:41 PM
Blum Robert IPresident & CEOJan 19 '24Option Exercise6.6712,50083,375454,297Jan 22 05:19 PM
Blum Robert IPresident & CEOJan 19 '24Sale81.4212,5001,017,750441,797Jan 22 05:19 PM
HENDERSON JOHN TDirectorJan 12 '24Option Exercise4.445,00022,20047,632Jan 12 05:20 PM
HENDERSON JOHN TDirectorJan 12 '24Sale85.145,000425,70042,632Jan 12 05:20 PM
Malik Fady IbrahamEVP Research & DevelopmentJan 04 '24Option Exercise7.9611,67892,957162,651Jan 04 04:36 PM
Malik Fady IbrahamEVP Research & DevelopmentJan 04 '24Sale86.9815,6781,363,712146,973Jan 04 04:36 PM
Blum Robert IPresident & CEOJan 02 '24Option Exercise6.6712,50083,375454,297Jan 02 05:55 PM
Blum Robert IPresident & CEOJan 02 '24Sale85.0812,5001,063,500441,797Jan 02 05:55 PM
WIERENGA WENDALLDirectorDec 27 '23Option Exercise4.4410,00044,40023,653Dec 27 04:11 PM
WIERENGA WENDALLDirectorDec 27 '23Sale73.6010,000736,00018,653Dec 27 04:11 PM
HENDERSON JOHN TDirectorDec 18 '23Option Exercise6.7213,02087,49444,838Dec 19 04:12 PM
Blum Robert IPresident & CEODec 18 '23Option Exercise6.6712,50083,375454,297Dec 19 04:13 PM
Blum Robert IPresident & CEODec 18 '23Sale36.9512,500461,875441,797Dec 19 04:13 PM
HENDERSON JOHN TDirectorDec 18 '23Sale36.342,45889,32442,380Dec 19 04:12 PM
Blum Robert IPresident & CEONov 30 '23Option Exercise6.6712,50083,375453,917Dec 01 04:15 PM
Blum Robert IPresident & CEONov 30 '23Sale32.9912,500412,375441,417Dec 01 04:15 PM
Blum Robert IPresident & CEONov 15 '23Option Exercise6.6712,50083,375453,917Nov 15 05:22 PM
Blum Robert IPresident & CEONov 15 '23Sale34.5712,500432,125441,417Nov 15 05:22 PM
Malik Fady IbrahamEVP Research & DevelopmentNov 09 '23Sale35.402,50088,500150,664Nov 09 04:35 PM
Blum Robert IPresident & CEOOct 30 '23Option Exercise6.6712,50083,375453,917Oct 30 04:02 PM
Blum Robert IPresident & CEOOct 30 '23Sale32.1712,500402,125441,417Oct 30 04:02 PM
Blum Robert IPresident & CEOOct 16 '23Option Exercise6.6712,50083,375453,917Oct 16 05:57 PM
Blum Robert IPresident & CEOOct 16 '23Sale33.7012,500421,250441,417Oct 16 05:57 PM
Malik Fady IbrahamEVP Research & DevelopmentOct 12 '23Sale35.892,50089,725153,164Oct 12 06:39 PM
Blum Robert IPresident & CEOOct 06 '23Option Exercise6.6712,50083,375453,917Oct 06 04:52 PM
Blum Robert IPresident & CEOOct 06 '23Sale30.0012,500375,000441,417Oct 06 04:52 PM
Malik Fady IbrahamEVP Research & DevelopmentSep 14 '23Sale34.862,50087,150155,664Sep 14 04:09 PM
Blum Robert IPresident & CEOSep 13 '23Option Exercise6.6712,50083,375453,917Sep 13 04:09 PM
Blum Robert IPresident & CEOSep 13 '23Sale34.9012,500436,206441,417Sep 13 04:09 PM
Blum Robert IPresident & CEOAug 25 '23Option Exercise7.7012,50096,275453,917Aug 28 06:45 PM
Blum Robert IPresident & CEOAug 25 '23Sale33.9912,500424,875441,417Aug 28 06:45 PM
WIERENGA WENDALLDirectorAug 21 '23Option Exercise6.726,02040,45424,225Aug 21 04:01 PM
WIERENGA WENDALLDirectorAug 21 '23Sale32.026,020192,76018,205Aug 21 04:01 PM
Blum Robert IPresident & CEOAug 11 '23Option Exercise9.5412,500119,287453,125Aug 11 04:18 PM
Blum Robert IPresident & CEOAug 11 '23Sale32.3712,500404,589441,417Aug 11 04:18 PM
Malik Fady IbrahamEVP Research & DevelopmentAug 10 '23Sale31.702,50079,250158,164Aug 10 04:14 PM
Blum Robert IPresident & CEOAug 01 '23Option Exercise9.6512,500120,625452,108Aug 01 04:57 PM
Blum Robert IPresident & CEOAug 01 '23Sale32.6312,500407,856441,417Aug 01 04:57 PM